ALX Oncology (NASDAQ:ALXO) Trading Down 3.6%

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) fell 3.6% on Tuesday . The company traded as low as $11.29 and last traded at $11.30. 62,676 shares were traded during mid-day trading, a decline of 83% from the average session volume of 360,338 shares. The stock had previously closed at $11.72.

Analysts Set New Price Targets

Several equities research analysts have commented on ALXO shares. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and increased their price objective for the company from $8.00 to $18.00 in a research note on Friday, December 8th. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, ALX Oncology has an average rating of “Moderate Buy” and an average target price of $18.42.

ALX Oncology Trading Down 2.3 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The company has a fifty day moving average price of $14.15 and a 200-day moving average price of $11.10.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, analysts predict that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jason Lettmann acquired 4,400 shares of ALX Oncology stock in a transaction on Thursday, March 14th. The shares were bought at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO Shelly Pinto sold 2,717 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $13.60, for a total transaction of $36,951.20. Following the sale, the chief accounting officer now owns 78,591 shares of the company’s stock, valued at $1,068,837.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jason Lettmann acquired 4,400 shares of ALX Oncology stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently bought and sold shares of ALXO. Swiss National Bank grew its position in ALX Oncology by 8.5% during the first quarter. Swiss National Bank now owns 19,200 shares of the company’s stock valued at $324,000 after buying an additional 1,500 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of ALX Oncology by 21.6% in the 1st quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock worth $326,000 after acquiring an additional 3,417 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of ALX Oncology by 58.5% in the first quarter. MetLife Investment Management LLC now owns 10,745 shares of the company’s stock valued at $182,000 after purchasing an additional 3,965 shares in the last quarter. BlackRock Inc. grew its position in shares of ALX Oncology by 1.1% in the 1st quarter. BlackRock Inc. now owns 1,355,478 shares of the company’s stock valued at $22,907,000 after buying an additional 14,907 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in ALX Oncology in the first quarter valued at $914,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.